Literature DB >> 17163590

Protective effect of astragalosides on myocardial injury by isoproterenol in SD rats.

Xiang-Jian Chen1, Dan Meng, Lin Feng, Yun-Yun Bian, Ping Li, Di Yang, Ke-Jiang Cao, Ji-Nan Zhang.   

Abstract

We have extracted and roughly purified astragalosides (AS) from Astragalus membranaceus, a natural herb used as a traditional Chinese medicine, regarded to have pharmacodynamic benefits of protecting injured myocardium. We hypothesized that the astragalosides might exert beneficial effect in myocardial lesion by preserving both energy metabolism and Ca(2+) homeostasis. Sprague-Dauley (SD) rats were injected with isoproterenol (ISO) subcutaneous (s.c.) at a dose of 5 mg/kg/day consecutively for two days as models and were treated with astragalosides and trimetazidine intraperitoneally (i.p.) respectively, at a dose of 5 mg/kg/day one day prior to isoproterenol for 8 days. The histological changes were alleviated in isoproterenol-injected SD rats treated with astragalosides. Compared with isoproterenol-injected rats, the concentration of myocardial intracellular [Ca(2+)]i was decreased, L-type Ca(2+) current density and sarcoplasmic reticulum (SR) Ca(2+) load were recovered, the concentration of myocardial ATP was increased and phosphocreatine (PCr) was decreased in rats treated with astragalosides. In conclusion, the efficacious treatment of astragalosides for myocardial injury might be through regulating intracellular Ca(2+) homeostasis and energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163590     DOI: 10.1142/S0192415X0600448X

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  7 in total

Review 1.  Research progress on mechanism of action of Radix Astragalus in the treatment of heart failure.

Authors:  Qing-You Yang; Ke-Ji Chen; Shu Lu; Hui-Ru Sun
Journal:  Chin J Integr Med       Date:  2012-04-02       Impact factor: 1.978

2.  The roles of buyang huanwu decoction in anti-inflammation, antioxidation and regulation of lipid metabolism in rats with myocardial ischemia.

Authors:  Yu Liu; Rong Lin; Xiaolian Shi; Zhiyuan Fang; Weirong Wang; Qinqin Lin; Jiye Zhang; Hui Zhang; Qiaoli Ji
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-10       Impact factor: 2.629

3.  Astragaloside-IV prevents acute kidney injury and inflammation by normalizing muscular mitochondrial function associated with a nitric oxide protective mechanism in crush syndrome rats.

Authors:  Isamu Murata; Yuji Abe; Yuka Yaginuma; Kayako Yodo; Yuka Kamakari; Yurika Miyazaki; Daichi Baba; Yuko Shinoda; Toru Iwasaki; Kunihiko Takahashi; Jun Kobayashi; Yutaka Inoue; Ikuo Kanamoto
Journal:  Ann Intensive Care       Date:  2017-09-04       Impact factor: 6.925

4.  Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1/Smad Signaling Pathway.

Authors:  Xingxing Yuan; Zhiqiang Gong; Bingyu Wang; Xueying Guo; Lei Yang; Dandan Li; Yali Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-30       Impact factor: 2.629

Review 5.  Modulatory Effects of Chinese Herbal Medicines on Energy Metabolism in Ischemic Heart Diseases.

Authors:  Fanghe Li; Jinmao Li; Saisai Li; Shuwen Guo; Ping Li
Journal:  Front Pharmacol       Date:  2020-07-03       Impact factor: 5.810

Review 6.  Emerging medical therapies in crush syndrome - progress report from basic sciences and potential future avenues.

Authors:  Ning Li; Xinyue Wang; Pengtao Wang; Haojun Fan; Shike Hou; Yanhua Gong
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

7.  Astragaloside IV promotes pharmacological effect of Descurainia sophia seeds on isoproterenol-induced cardiomyopathy in rats by synergistically modulating the myosin motor.

Authors:  Xingkai Liu; Qian Chen; Xuming Ji; Wanchen Yu; Tong Wang; Juanjuan Han; Shumu Li; Jianan Liu; Fangang Zeng; Yao Zhao; Yanyan Zhang; Qun Luo; Shijun Wang; Fuyi Wang
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.